This growing mobile ordering startup has rebranded to represent its growth. Photo courtesy of sEATz

The Houston startup that enabled in-seat food and beverage ordering at stadiums has grown over the past few years — and the company has entered into its new era with a rebrand.

Houston-based sEATz expanded this year to evolve its technology to enable optimized mobile ordering within hospitals. Launching that new platform, called myEATz, led to a need for a defined parent company to account for the growing company. Rivalry Technology will be run by the same sEATz and myEATz team.

“I always knew that sEATz would grow into something special," says Rivalry Tech CEO and Co-Founder Aaron Knape in a news release. "As we continue to expand and grow, our brand has also grown with it. With sEATz holding sway over Sports and Entertainment, and the myEATz platform making rapid inroads into healthcare, business dining and leisure, the Rivalry Tech branding will help pull it all together.”

The rebrand comes with a new logo, website, and social media accounts. Rivalry's chief of staff, Megan Fier, designed the new logo with sEATz's original design and colors in mind.

“Knowing how recognized the sEATz brand has become, I needed to design the Rivalry Tech logo to compliment that," she says in the release. "The dual arrows pointing together represent our two platform brands. The orange sEATz half shows where we started while the navy blue myEATz shows where we are going.”

The new website also showcases both brands with information for those interested in both platforms.

“Prior to our rebrand, we had two separate websites presenting as two separate companies," Fier says. "I wanted our website to be our go-to place for both sEATz and myEATz, to show that cohesion and showcase the depth of our offerings as Rivalry Tech. The new Rivalry Tech website shares our products, tells our story, and gives site visitors a place to connect to our team all in one website. Afterall, we are more than just mobile ordering.”

The name reflects the three sEATz co-founders' alma maters: Knape graduated from Texas A&M University, Marshall Law from the University of Texas, and Craig Ceccanti from Louisiana State University.

“An Aggie, a Longhorn, and an LSU Tiger walked into a bar," Knape explains, "and it was the only name on which we could agree.“

Founded in 2018, the company has raised two seed rounds — one in 2019 and another amid the pandemic in 2020. Following that funding, Knape previously told InnovationMap that he's focused on the company's growth.

"I tell the team that we're kind of coming out of stealth mode — I know we're not in a true stealth mode, but we haven't spent a lot of money on sales and marketing," Knape says on the Houston Innovators Podcast. "Now it's time to start putting that emphasis on who we are, that we're here, and we're ready to take over."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”